Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Attractants prevent maturing nerve cells from migrating into brain

A vision is to implant nerve precursor cells in the diseased brains of patients with Parkinson's and Huntington's diseases, whereby these cells are to assume the function of the cells that have died off.

21 Nov 2013

Omeros’ OMS302 reduces incidence of miosis during intraocular lens replacement in Phase 3 clinical trial

Omeros Corporation today reported analyses of Phase 3 clinical data showing the impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular lens replacement. OMS302 is the company's proprietary Pharmacosurgery product being developed for all ILR, including cataract surgery and refractive lens exchange.

20 Nov 2013

Meclizine drug has the potential to treat certain infectious diseases and cancer

Meclizine, an over-the-counter drug used for decades to treat nausea and motion sickness, has the potential for new uses to treat certain infectious diseases and some forms of cancer, according to Dr. Vishal M. Gohil, Texas A&M AgriLife Research biochemist.

31 Oct 2013

Diverse Neurological Disorders Appear To Share Tangled Metabolic Roots

...

10 Oct 2013

Lundbeck, Otsuka to continue development of Lu AE58054 compound for Alzheimer's disease

H. Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd. announced today the continuation of the development program of Lu AE58054 for the treatment of Alzheimer's disease, initiating the first out of four phase III clinical trials with the compound.

10 Oct 2013

Omeros' OMS824 gets FDA orphan drug designation for treatment of Huntington's disease

Omeros Corporation announced that OMS824, its phosphodiesterase 10 inhibitor, has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of Huntington's disease.

30 Sep 2013

Stem cell lines are ideal research tools for designing models to understand disease progression

Scientists from King's College London have announced that 16 human embryonic stem (hES) cell lines have been approved by the US National Institutes of Health (NIH) and placed on their Stem Cell Registry, making them freely available for federally-funded research in the USA.

25 Sep 2013

Omeros announces initiation of enrollment in OMS824 Phase 2 trial for schizophrenia

Omeros Corporation today announced initiation of enrollment in a Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 inhibitor. The trial will evaluate the compound's tolerability, safety, pharmacokinetics, potential interactions with concomitant antipsychotic medications, and a battery of cognitive tests in patients with stable schizophrenia.

19 Sep 2013

Researchers identify likely molecular pathway that causes untreatable neurodegenerative diseases

University of Adelaide researchers have identified a likely molecular pathway that causes a group of untreatable neurodegenerative diseases, including Huntington's disease and Lou Gehrig's disease.

19 Sep 2013

Omeros announces positive data from OMS824 Phase 1 clinical trial

Omeros Corporation today announced positive data from the Company's Phase 1 clinical trial evaluating the pharmacokinetics of OMS824, the lead compound in Omeros' phosphodiesterase 10 program, further supporting that OMS824 can achieve superior target engagement with lesser side effects compared to other PDE10 inhibitors in development.

12 Sep 2013

Resveratrol improves cognition and reduces oxidative stress in rats with vascular dementia

Resveratrol, a polyphenolic compound, is synthesized in several plants and possesses beneficial biological effects, which include anti-oxidant, anti-inflammatory and anti-carcinogenic properties.

5 Sep 2013

Adhering to MedDi does not appear associated with time to clinical onset of HD

Adhering to a Mediterranean-type diet (MedDi) does not appear associated with the time to clinical onset of Huntington disease (phenoconversion), according to a study by Karen Marder, M.D., M.P.H., of Columbia University College of Physicians and Surgeons, New York, N.Y., and colleagues.

3 Sep 2013

Blood test provides tool essential to trials of therapies for Huntington's disease

An assay designed to measure normal and abnormal forms of the huntingtin protein - the mutated form of which causes Huntington's disease - was successful in detecting levels of the mutant protein in a large multicenter study of individuals at risk for the devastating neurological disorder.

30 Aug 2013

Alzheimer’s drug trial: an interview with Geoffrey Kempler, Chairman & CEO Prana Biotechnology

Approval for the IMAGINE trial was granted by the Austin Health Research Ethics Committee in November 2011, with the first patients dosed in March the following year. However, well before the trial was approved, PBT2 had already shown promise in significantly changing Abeta levels in spinal fluid while improving cognition in a previous 12-week trial conducted in 2006.

28 Aug 2013

ASO may correct striatal transcriptional abnormalities and improve behavioral problems in HD mice

Findings from postmortem studies of the brains of Huntington's Disease (HD) patients suggest that transcriptional dysregulation may be an early step in the pathogenesis of HD before symptoms appear. Other studies report transcriptional alterations in the brains of some mouse models of HD.

27 Aug 2013

Sangamo BioSciences signs definitive agreement to buy Ceregene

Sangamo BioSciences, Inc. announced that it signed a definitive agreement to acquire Ceregene, Inc., a privately held biotechnology company focused on developing adeno-associated virus gene therapies.

26 Aug 2013

Glutathione peroxidase activity protects against symptoms of Huntington's disease

Leicester geneticists have discovered a potential defence against Huntington's disease - a fatal neurodegenerative disorder which currently has no cure.

26 Aug 2013

Psychogenics Picks Up Alzheimer’s Animal Model From USF

PsychoGenics obtained an exclusive license from the University of South Florida to its APP/PS1 double transgenic mice, which co-express the M146L presenilin 1 (PS1) mutation and the double mutations at K670N/M671L (Swedish mutation) in the amyloid precursor protein (APP).

22 Aug 2013

Research suggests Huntington's disease might begin in synapses

The synapses in the brain act as key communication points between approximately one hundred billion neurons. They form a complex network connecting various centres in the brain through electrical impulses. New research from Lund University suggests that it is precisely here, in the synapses, that Huntington's disease might begin.

13 Aug 2013

Omeros announces financial results for second quarter of 2013

Omeros Corporation, a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the second quarter of 2013.

12 Aug 2013

Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Attractants prevent maturing nerve cells from migrating into brain

Omeros’ OMS302 reduces incidence of miosis during intraocular lens replacement in Phase 3 clinical trial

Meclizine drug has the potential to treat certain infectious diseases and cancer

Diverse Neurological Disorders Appear To Share Tangled Metabolic Roots

Lundbeck, Otsuka to continue development of Lu AE58054 compound for Alzheimer's disease

Omeros' OMS824 gets FDA orphan drug designation for treatment of Huntington's disease

Stem cell lines are ideal research tools for designing models to understand disease progression

Omeros announces initiation of enrollment in OMS824 Phase 2 trial for schizophrenia

Researchers identify likely molecular pathway that causes untreatable neurodegenerative diseases

Omeros announces positive data from OMS824 Phase 1 clinical trial

Resveratrol improves cognition and reduces oxidative stress in rats with vascular dementia

Adhering to MedDi does not appear associated with time to clinical onset of HD

Blood test provides tool essential to trials of therapies for Huntington's disease

Alzheimer’s drug trial: an interview with Geoffrey Kempler, Chairman & CEO Prana Biotechnology

ASO may correct striatal transcriptional abnormalities and improve behavioral problems in HD mice

Sangamo BioSciences signs definitive agreement to buy Ceregene

Glutathione peroxidase activity protects against symptoms of Huntington's disease

Psychogenics Picks Up Alzheimer’s Animal Model From USF

Research suggests Huntington's disease might begin in synapses

Omeros announces financial results for second quarter of 2013

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in